Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label multiple-dose study of RZ358 in congenital hyperinsulinism
2016-004186-83Phase 2Unknown
- Sponsor
- Rezolute, Inc.
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ersodetug in congenital hyperinsulinism (HI), sponsored by Rezolute, Inc. Primary endpoint: Glycemic efficacy by CGM. Status: unknown.
02
Drugs
ersodetug
03
Conditions
congenital hyperinsulinism (HI)
Beyond the preview
Go deeper on 2016-004186-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004186-83.